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A THE indications for anticoagulant therapy become more extended, some problems in the management of anticoagulant therapy with coumarin derivatives and their laboratory control become increasingly important.
Until recently very little was known about the mode of action of coumarin derivatives. It has been shown that the activity of factor VII and subsequently of prothrombin decreases during coumarin therapy. This diminution is usually directly related to the antithrombotic activity of coumarin derivatives. Douglas ' has recently shown that the prothrombin level of the blood does not fall below 50 per cent of normal during adequate therapy with 3,3'-carboxymethylenebis (4 -hydroxycoumarin) ethyl ester (Tromexan) . The prolongation of the prothrombin time by the 1-stage method is partly due to the deficiency of factor VII and the moderate depression of prothrombin is insufficient to decrease blood coagulability. Recent studies have also demonstrated that the activity of other clotting factors, such as plasma thromboplastin component (PTC, factor IX, Christmas factor) 2' 3 and factor X4 5 decreases during coumarin therapy. The influence of coumarin derivatives on the latter 2 factors is not detected by the 1-stage prothrombin determination because potent tissue throm- boplastin by-passes the first phase of the clotting mechanism in which both components participate. If the diminished activity of PTC and factor X is partly responsible for the desired hypocoagulability of the blood, the 1-stage prothrombin time method gives an incomplete account of the coumarin-induced changes. The heparin tolerance test, as a complementary test to prothrombin determinations, has given important information for the evaluation of the action of anticoagulants.6 7 This technic, however, is too cumbersome to become a routine procedure. ' Other problems are the presumably changing sensitivity of a given patient to a coumarin derivative and the varying dosage requirements by different individuals. These changes are evaluated on the basis of prothrombin assays carried out in the same laboratory with identical reagents.
oxalate in the proportion of 9 parts blood to 1 part sodium oxalate. Tubes that appeared to be underfilled or overfilled were rejected. The oxalated blood was centrifuged at 1,700 r.p.m. for 10 minutes and the plasma was removed.
Collection of Serum. Five to 10 ml. of venous blood were placed in a centrifuge tube. The clotted blood was stored in a water bath at 37 C. for at least 4 hours before the serum was removed. The presence of free thrombin in the serum was evaluated by adding 0.1 ml. of serum to 0.1 ml. of fibrinogen at 37 C. (fibrinogen Warner-Chilcott 300 mg. per cent). The prothrombin content was assessed in the mixture of 0.1 ml. of serum and 0.1 ml. of barium sulfatetreated plasma by adding 0.2 ml. of thromboplastincalcium chloride suspension and observing the clotting time. For these experiments the rabbit lung extract, Difeo-Aplastin, was used. Fifty milligrams of dried lung extract were suspended in 2.5 ml. of 0.85 per cent sodium chloride and mixed with 2.5 ml. of 0.02 M calcium chloride.
Preparation of T/hromboplastins. Eight different commercial thromboplastin extracts wmere selected for this study. They were prepared in accordance with the methods described by the manufacturers. There were 4 rabbit lung preparations (Difeo-Aplastin, Geigy Thromboplastin, Roche Thromboplastin, Warner-Chilcott Thromboplastin), 2 fig. 2A-D In conclusion, for each thromboplastin tested, different dilution curves were obtained for the various diluents.
In an analysis of the data obtained with 4 different thromboplastins, a definite difference was noted between the plasma dilution curves for thromboplastin extracts derived from rabbit brain (A-P, D-T) and rabbit lung respectively (D-A, W.C.-T.). With the brain preparations there was only a moderate difference between the 1-stage prothrombin times in corresponding plasma concentration, with oxalated imidazole buffer or barium sulfate-treated normal plasma as diluent. Neither of the corresponding curves had a diverging slope in the lower plasma concentrations (curves B and C of fig. 2A ministered orally to fasting rabbits, and blood was taken by cardiac puncture when the hypocoagulability was so marked that external bleeding occurred. The 1-stage prothrombin time of the pooled rabbit plasma was more than 3 minutes. The prothrombin time of normal rabbit plasma, tested with the same thromboplastin, ranged between 7 and 9 seconds (rabbit lung preparation D-A). Normal fresh rabbit plasma was diluted with the coumarin rabbit plasma and the 1-stage prothrombin time was determined with 2 brain thromboplastins (A-P and D-T), 2 lung thromboplastins (G-T and R-T), and 2 thromboplastins that are a mixture of lung and brain extracts (S-S and W.C.-S.). The same experiments were repeated on normal rabbit plasma diluted with barium sulfate-treated rabbit plasma. The results of these tests are shown in figure 3 . From a consideration of a given thromboplastin, it is clear that the dilution curves with barium sulfate-treated rabbit plasma or coumarin rabbit plasma are practically superimposable. If fig. 4 ). This result indicates that the basic difference between both groups of preparations is not directly related to the optimal concentration of materials that induce blood coagulation nor to the proportional concentration of substances that enhance or inhibit clotting.
The activity of both types of thromboplastin were further investigated in systems containing decreasing concentrations of prothrombin or factor VII. The clottable substrate consisted of 0.1 ml. of normal plasma diluted to various concentrations with the same plasma previously treated with barium sulfate. Added to this mixture were 0.1-ml. samples of either factor VII-free plasma containing prothrombin (citrated human plasma filtered through a 20 per cent asbestos filter pad) or prothrombin-free serum, containing factor VII. The factor VII-"free" plasma or prothrombin-"free" serum was diluted with oxalated imidazole buffer to complement the dilutions of the normal plasma (i.e., 0.1 ml. of 75 per cent normal plasma and 0.1 ml. of 25 per cent serum or factor VII-free plasma).
Filtration through 20 per cent asbestos pads renders human citrated plasma free of factor VII and removes only 10 to 20 per cent of the original prothrombin concentration of the plasma. It is, however, important not to use the first 10-ml. filtrate, which is poor in prothrombin as well. Once the filter pad is saturated with prothrombin, only factor VII is adsorbed. Care should be taken not to overuse the filter beyond its adsorption capacity for factor VII The serum samples were free of active thrombin and the traces of remaining prothrombin were too small to interfere significantly in the experiments. The influence of salts, the pH, and the protein concentration on the 1-stage prothrombin time test and fibrinogen conversion has been stressed recently. '6 17 The specimens were, therefore, diluted with oxalated buffer in order to keep the oxalate content and pH in the final mixture constant.
The thromboplastins were diluted with 0.25 M calcium chloride to the same extent as the normal plasma diluted with barium sulfatetreated plasma. The results of these experiments are shown in figures 5A and 5B. The points plotted represent the mean of 3 experiments performed in duplicate on 3 different days (tables 1 and 2).
When the factor VII content in the system was constant and the prothrombin level the only variable ( fig. 5A) .!X, The thromboplastin suspensions were diluted with CaC12 M/40 to the same extent as the prothrombin concentration.
The factor VII content of the mixture is kept constant in these experiments. The thromboplastin suspensions were diluted with one-fortieth molar CaC12 to the same extent as the factor VII.
The prothrombin content of the mixture is kept constant in these experiments. (table 4) . Even in a concentration of 50 mg. of barium sulfate per ml. of mixture, significant changes in the activity of brain thromboplastin were not noted. A lung preparation had a pronounced decrease in activity after similar treatment, even when very low concentrations of barium sulfate were used (2.5 mg./ml.).
The addition of 1 ml. of normal serum to 5 ml. of thromboplastin-calcium chloride mixture enhanced the activity of brain and lung preparations. A moderately prolonged coumarin plasma reached even shorter values than the normal control time (table 5) . If the serum (2 ml.) was shaken with ether (2 ml.) for 2 hours at room temperature before mixing with thromboplastin-calcium chloride, the 1-stage prothrombin time of the same coumarin plasma became equal to the control time (table 5B) . However, if the serum was treated with barium sulfate before mixing with the thromboplastin-calcium chloride, the 1-stage prothrombin times became longer as compared with times obtained with regular thiomboplastin (table 5C) .
A further differentiation between lung and brain preparations could not be obtained by heating of the thromboplastin-calcium chloride mixtures to 60 C. or 90 C. for 10 minutes, because the activity decreased rapidly for both preparations.
DIscussIoN
According to our clinical experience, the 1-stage plasma prothrombin time test is still the preferred method for the measurement of the action of coumarin derivatives. Although the exact influences of these compounds on the blood clotting factors are still obscure, the decrease of prothrombin and factor VII activity should be the guide for the administration of anticoagulants. Because coumarin derivatives produce a factor VII deficiency that may lead to bleeding without a striking depression of prothrombin, it is essential to evaluate factor VII in the plasma.
In order to make the 1-stage prothrombin time test reflect the factor VII and prothrombin content of the plasma, the thromboplastin used should be devoid of these factors. For example, Russell's viper venom combined with lipids had to be discarded because it possessed "convertin" activity.l" When the action of rabbit brain and lung tissue thromboplastins was compared on plasmas of patients treated with coumarin derivatives, shorter times were obtained with brain preparations. In comparing the 2 groups of thromboplastins, it was found that both have a similar activity in a system with a fixed factor VII and decreasing prothrombin content. Brain preparations, however, gave significantly shorter times than lung thromboplastins if tested in a system with a fixed content of prothrombin but a decreased level of factor VII.
One possible interpretation of the observed difference between rabbit lung and brain thromboplastins is that brain preparations have a factor VII-like activity that does not seem to be present in lung preparations. Therefore, rabbit brain thromboplastins are more active than lung preparations in blood samples in which the concentration of factor VII is depressed. However, they have the same activity as lung preparations when the clotting system has a normal factor VII activity but low prothrombin activity.
The mode of action of rabbit brain thromboplastin is, therefore, similar to Russell's viper venom combined with lipids, which is considered to have a "convertin" activity (equivalent to the combination of antihemophilic globulin, PTC., factor VII and platelet lipid factor).18, 9 The activity of the Russell's viper venom-lipid suspension is, however, eonsiderably higher than that of brain extracts. The action of brain thromboplastin in the plasma prothrombin time is, therefore, partly independent of the factor VII content of the plasma tested. The practical clinical consequence is that when laboratories use brain thromboplastin, the clinicians have to give higher doses of coumarin derivatives in order to obtain the commonly accepted therapeutic prothrombin time than when the slower acting lung thromboplastin is used. A striking illustration of this is a large hospital where 2 laboratories are doing prothrombin times, using 2 Most authors agree that the therapeutic range of the 1-stage prothrombin time is between 25 and 35 seconds or 1 12 to 21 the control time. Although most thromboplastins have a rather identical prothrombin time on fresh plasma, normal plasma has to be diluted much more to reach this therapeutic range, if a rabbit brain preparation rather than a lung preparation is used. To obtain a 1-stage prothrombin time of 30 seconds, normal plasma has to be diluted with barium sulfate-treated plasma to 34 per cent and 30 per cent if the prothrombin tests are performed with brain preparations (A-P and D-T respectively) and to 60 per cent and 45 per cent if a lung preparation is used (D-A and W.C.-T. respectively).
These observations indicate the hazard of referring to a prothrombin time without mentioning the control time, the type of diluent, and the thromboplastin used. In view of the marked difference in activity, it is almost impossible to determine a general therapeutic range for all thromboplastins commercially available. Previous attempts were based on the erroneous assumption that the thromboplastins are of fairly uniform activity.
Dilution curves of normal plasma with different diluents (0.85 per cent sodium chloride, imidazole buffer pH 7.4, oxalated buffer and barium sulfate-treated normal plasma) are quite different for each thromboplastin tested, although the different slopes are more similar for brain preparations than for lung preparations. When prothrombin times are reported in terms of concentrations of prothrombin, the diluent chosen to make the dilution graph should, therefore, be mentioned. As can be seen in figure 2D, Several factors of the clotting mechanism are influenced by coumarin derivatives. The action of some of these factors is by-passed in the 1-stage prothrombin time test. The decrease of the prothrombin and factor VII levels may be evaluated in the 1-stage prothrombin time determination (Quick test) . The prolongation of the prothrombin times are, however, predominantly due to the decrease of factor VII activity, the prothrombin content, remaining around 50 per cent of normal during an adequate anticoagulant therapy. It is unlikely that this degree of depression of prothrombin is of major significance in interfering with the coagulation mechanism in the protection against thromboembolism. It may, however, play a minor role, which has yet to be evaluated quantitatively. An The prothrombin times of clottable mixtures wvith a constant factor VII content and decreasing prothrombin activity obtained with lung and brain thromboplastins are spread over a small area. The same thromboplastins tested in a system with constant prothrombin activity but decreasing factor VII content give widespread prothrombin times. Brain preparations give short times; lung preparations give long times, and mixtures of lung and brain preparations take an intermediate position. The main difference between both thromboplastin extracts seems to be that brain preparations have a factor VII-like activity.
As the exact evaluation of the factor VII activity seems to be of primary importance in patients treated with coumarin derivatives, the use of a thromboplastin preparation devoid of factor VII activity is recommended. 
